133 related articles for article (PubMed ID: 21982018)
1. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Kutikov A; Makhov P; Golovine K; Canter DJ; Sirohi M; Street R; Simhan J; Uzzo RG; Kolenko VM
Urology; 2011 Oct; 78(4):968.e7-11. PubMed ID: 21982018
[TBL] [Abstract][Full Text] [Related]
2. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Saylor PJ; Mahmood U; Kunawudhi A; Smith MR; Palmer EL; Michaelson MD
J Nucl Med; 2012 Nov; 53(11):1670-5. PubMed ID: 22984218
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
5. Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
Spanheimer PM; Lorenzen AW; De Andrade JP; Kulak MV; Carr JC; Woodfield GW; Sugg SL; Weigel RJ
Ann Surg Oncol; 2015 Dec; 22(13):4287-94. PubMed ID: 25971960
[TBL] [Abstract][Full Text] [Related]
6. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Canter D; Kutikov A; Golovine K; Makhov P; Simhan J; Uzzo RG; Kolenko VM
Can J Urol; 2011 Aug; 18(4):5819-25. PubMed ID: 21854714
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Shablak A; Gilham DE; Hawkins RE; Elkord E
Expert Opin Pharmacother; 2014 Aug; 15(11):1489-99. PubMed ID: 24890457
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
[TBL] [Abstract][Full Text] [Related]
9. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
10. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of sunitinib in men with advanced prostate cancer.
Dror Michaelson M; Regan MM; Oh WK; Kaufman DS; Olivier K; Michaelson SZ; Spicer B; Gurski C; Kantoff PW; Smith MR
Ann Oncol; 2009 May; 20(5):913-20. PubMed ID: 19403935
[TBL] [Abstract][Full Text] [Related]
13. Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Damaraju VL; Kuzma M; Mowles D; Cass CE; Sawyer MB
Mol Cancer Ther; 2015 Jan; 14(1):236-45. PubMed ID: 25519698
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract][Full Text] [Related]
15. Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Cancer Genomics Proteomics; 2015; 12(6):391-6. PubMed ID: 26543085
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
Makhov PB; Golovine K; Kutikov A; Teper E; Canter DJ; Simhan J; Uzzo RG; Kolenko VM
Mol Cancer Ther; 2012 Jul; 11(7):1510-7. PubMed ID: 22532600
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Santoni M; Amantini C; Morelli MB; Liberati S; Farfariello V; Nabissi M; Bonfili L; Eleuteri AM; Mozzicafreddo M; Burattini L; Berardi R; Cascinu S; Santoni G
Br J Cancer; 2013 Aug; 109(4):1040-50. PubMed ID: 23887605
[TBL] [Abstract][Full Text] [Related]
19. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
